ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of AUD 56.97 billion. The enterprise value is 56.80 billion.

Market Cap	56.97B
Enterprise Value	56.80B

Important Dates

The last earnings date was Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	May 7, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.07%
Shares Change (QoQ)	-0.18%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.69M

Valuation Ratios

The trailing PE ratio is 27.05 and the forward PE ratio is 24.27.

PE Ratio	27.05
Forward PE	24.27
PS Ratio	7.08
PB Ratio	6.41
P/TBV Ratio	15.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.96, with an EV/FCF ratio of 22.58.

EV / Earnings	26.98
EV / Sales	7.21
EV / EBITDA	19.96
EV / EBIT	22.42
EV / FCF	22.58

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.15.

Current Ratio	3.41
Quick Ratio	2.06
Debt / Equity	0.15
Debt / EBITDA	0.46
Debt / FCF	0.54
Interest Coverage	139.28

Financial Efficiency

Return on equity (ROE) is 25.81% and return on invested capital (ROIC) is 16.54%.

Return on Equity (ROE)	25.81%
Return on Assets (ROA)	14.01%
Return on Invested Capital (ROIC)	16.54%
Return on Capital Employed (ROCE)	24.33%
Revenue Per Employee	806,765
Profits Per Employee	210,989
Employee Count	9,980
Asset Turnover	0.70
Inventory Turnover	2.09

Taxes

In the past 12 months, ResMed has paid 335.18 million in taxes.

Income Tax	335.18M
Effective Tax Rate	18.95%

Stock Price Statistics

The stock price has increased by +18.37% in the last 52 weeks. The beta is 0.78, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.78
52-Week Price Change	+18.37%
50-Day Moving Average	35.52
200-Day Moving Average	36.34
Relative Strength Index (RSI)	68.50
Average Volume (20 Days)	1,399,740

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.76

Income Statement

In the last 12 months, ResMed had revenue of AUD 8.05 billion and earned 2.11 billion in profits. Earnings per share was 14.29.

Revenue	8.05B
Gross Profit	4.78B
Operating Income	2.58B
Pretax Income	2.53B
Net Income	2.11B
EBITDA	2.83B
EBIT	2.58B
Earnings Per Share (EPS)	14.29

Full Income Statement

Balance Sheet

The company has 1.51 billion in cash and 1.35 billion in debt, giving a net cash position of 168.47 million.

Cash & Cash Equivalents	1.51B
Total Debt	1.35B
Net Cash	168.47M
Net Cash Per Share	n/a
Equity (Book Value)	8.89B
Book Value Per Share	60.65
Working Capital	3.64B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.65 billion and capital expenditures -134.94 million, giving a free cash flow of 2.52 billion.

Operating Cash Flow	2.65B
Capital Expenditures	-134.94M
Free Cash Flow	2.52B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.37%, with operating and profit margins of 32.10% and 26.15%.

Gross Margin	59.37%
Operating Margin	32.10%
Pretax Margin	31.41%
Profit Margin	26.15%
EBITDA Margin	35.14%
EBIT Margin	32.10%
FCF Margin	31.24%

Dividends & Yields

This stock pays an annual dividend of 0.49, which amounts to a dividend yield of 1.27%.

Dividend Per Share	0.49
Dividend Yield	1.27%
Dividend Growth (YoY)	9.61%
Years of Dividend Growth	n/a
Payout Ratio	23.14%
Buyback Yield	0.07%
Shareholder Yield	1.34%
Earnings Yield	3.70%
FCF Yield	4.42%

Dividend Details

Stock Splits

The last stock split was on August 12, 2010. It was a forward split with a ratio of 2.

Last Split Date	Aug 12, 2010
Split Type	Forward
Split Ratio	2

Scores

ResMed has an Altman Z-Score of 12.61 and a Piotroski F-Score of 5.

Altman Z-Score	12.61
Piotroski F-Score	5